Skip to contentI
Intelligent Bio Solutions Inc.
I
INBSIntelligent Bio Solutions Inc. Q4 2026 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.15M$1.15Mderived+35.8% vs Q4 2025 Net Income-$3.91M-$3.91MderivedN/M vs Q4 2025 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Intelligent Bio Solutions Inc. · CIK 1725430 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$536,583+59.9% Operating Incomederived-$4,025,653N/M Operating Cash Flowderived-$3,182,308N/M Free Cash Flowderived-$3,182,308— Margins · derivedGross margin46.8%+7.1 pt vs Q4 2025
Operating margin-351.3%+19.5 pt vs Q4 2025
Net margin-341.0%+25.1 pt vs Q4 2025
ended Jun 30, 2026 · filed Aug 19, 2026 · 50 d after period end